14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ABUS vs IONX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Arbutus Biopharma Corporation (ABUS) is the stronger overall head-to-head candidate over Defiance Daily Target 2X Long IONQ ETF (IONX) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABUS carries a Unified Composite Score of 56.1/100 (HOLD) at $4.04 (10.2x Forward P/E, 80.1% operating margin), whereas IONX carries 48.8/100 (HOLD) at $8.27 (N/M Forward P/E, N/A operating margin).
Technical & Structure Timing Caution: ABUS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.0); meanwhile IONX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABUS vs IONX. Trailing 12-month operating profitability (ABUS 80.1% vs IONX N/A) and valuation multiples (ABUS 10.2x vs IONX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ABUS vs IONX Key Questions & Quantitative Answers
As of Nov 16, 2026, Arbutus Biopharma Corporation (ABUS) is the stronger overall head-to-head candidate over Defiance Daily Target 2X Long IONQ ETF (IONX) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABUS carries a Unified Composite Score of 56.1/100 (HOLD) at $4.04 (10.2x Forward P/E, 80.1% operating margin), whereas IONX carries 48.8/100 (HOLD) at $8.27 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: ABUS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.0); meanwhile IONX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ABUS leads the Growth & Scale pillar: ABUS posts -43.5% YoY revenue growth and +0.0% YoY earnings growth on $181M TTM revenue (91.9% gross margin, 80.1% operating margin), compared with IONX at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ABUS generates $181M in USD-normalized revenue versus N/A for IONX. In operating R&D and SG&A reinvestment, ABUS deploys 11.8% of Rev ($21M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IONX.
ABUS screens cheaper on headline valuation multiples. ABUS trades at 10.2x Forward P/E, 3.6x Trailing P/E, N/M PEG, and 2.0x EV/Revenue (unreported FCF margin), whereas IONX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABUS (269.6% ROE) versus IONX (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, ABUS carries 72.9% implied volatility (28th %ile, Balanced (25th–60th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.20β · 51% Vol realized risk). By comparison, IONX carries 181.8% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (6.79β · 232% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.